EGFR and neoplasm: Cetuximab, a monoclonal antibody against EGFR, blocks EGFR pathway signaling mainly by competitively suppressing the binding action of EGFR to related ligands, which can kill EGFR‐positive OS cells by enhancing the cytolytic function of NK cells and inhibit distant tumor invasion and angiogenesis.319